CCO Oncology Podcast

Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management

Episode Summary

Listen to expert hematologists provide an up-to-date clinical overview of paroxysmal nocturnal hemoglobinuria (PNH), exploring its pathogenesis, clinical manifestations, and the evolution of complement-based therapies.

Episode Notes

In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes and quality of life. The conversation blends clinical insights with practical considerations for therapy selection and patient care, including:

• The pathogenesis of PNH and the role of complement activation
• Landmark therapies such as eculizumab and ravulizumab
• Advances in proximal inhibitors (eg, pegcetacoplan, iptacopan, danicopan)
• Quality-of-life considerations, treatment personalization, and emerging therapies

Presenters:

Carlos M. De Castro, MD
Professor of Medicine, DUMC
Division of Malignant Hematology and Cellular Therapy
Department of Medicine
Duke University
Duke Cancer Institute
Durham, North Carolina

David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath
Consultant Hematologist and Director of Bone Marrow Transplant Program
Professor of Medicine
Division of Hematology
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Link to full program:
https://bit.ly/3Jtjqgr